Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
-
Markel Canada Limited Appoints Senior Vice President, Underwriting
-
Better.com Launches Loyalty Rewards Program to Provide Lifetime Savings for Homeowners
-
DigitalOcean Announces 2025 Investor Day
-
Landus and TalusAg Deliver First Local Green Ammonia Production in North America
-
Lifesum Transforms Meal Tracking with AI-Powered Multimodal Tracker for Personalized Nutrition
-
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
Lumos Expands Into Alabama, Building Nearly 105K Miles of its 100% Fiber Optic Internet to Reach Nearly 100K Passings in Birmingham Metro
-
Versa Named SASE Industry Leader and Outperformer in GigaOm® Radar™ Report
-
Flatiron Health and Exact Sciences Partner to Advance Clinical Evidence Generation for Molecular Residual Disease Testing
-
New Email Security Solutions from InsurSec Leader At-Bay Help Eliminate Financial Fraud Claims
-
Qlaris Bio Announces Positive Topline Data From Two Phase II Trials of QLS-111 in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
-
Omdia: MVNO Market on the Rise as Global Subscriptions to Grow 3.6% CAGR by 2029
-
Wisedocs Unveils WiseChat and Custom Reports to Simplify Medical Record and Claims Reviews with AI
-
Willis appoints Stephen Kyriacou Head of Litigation and Contingent Risk Solutions in North America
-
Rezolve Ai Kicks Off 2025 with Major Retail Expansion as Leading Brands Leverage Its Cutting-Edge Technology
-
Alice Group USA Announces Acquisition Strategy and Transformation of TFLM
-
Algorhythm Holdings Announces Date and Ratio of Reverse Stock Split
-
Music of Your Life Gears Up for Milestone 50th Anniversary Celebration
-
Oxbridge / SurancePlus Selects Coinbase Prime to Support Strategic Investments in Digital Assets
-
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
-
Xsolis Ranked No. 1 Best in KLAS for Physician Advisory Services for Fourth Year
-
Katana Cloud Inventory Launches Integration Marketplace and a New Multisite Order Feature to Simplify and Optimize Business Operations
-
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-
SunOpta Inc. Schedules Fourth Quarter and Fiscal 2024 Financial Results Release and Conference Call
-
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
-
Vertiv to Participate in Upcoming Conferences
-
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
-
WillScot to Announce Fourth Quarter 2024 Results on February 20, 2025
-
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
-
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
-
Systemic Bio Wins the SLAS 2025 Innovation Award
-
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
-
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndro
-
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
-
AXIL Brands to Debut its MX Series of Over-the-Ear Hearing Protection Products at NASCAR Daytona 500
-
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
-
Stryker declares an $0.84 per share quarterly dividend
-
Collegium Appoints Nancy S. Lurker to its Board of Directors
-
R1 Wins ‘Best in KLAS’ Across Multiple RCM Categories for 2025
-
Health Catalyst to Announce Fourth Quarter and Full Year 2024 Operating Results and Host Conference Call on Wednesday, February 26, 2025
-
MIMEDX to Host Fourth Quarter and Full Year 2024 Operating and Financial Results Conference Call on February 26
-
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
-
Constellium to Report Fourth Quarter and Full Year 2024 Results on February 20, 2025
-
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
-
E-Star BioTech Announces Dosing of First Patient in Phase 2 Clinical Trials of MANP in Resistant Hypertension
-
TransUnion Introduces TruVision Alternative Bank Risk Score to Help Lenders Better Assess Consumers with Limited Credit Histories
-
Nextech Wins Two Best in KLAS Awards, Earning Top Honors in Dermatology and Ophthalmology
-
Lifeward Finalizes Personal Exoskeleton Reimbursement Agreement with BARMER, Adding 8.5 Million Covered Lives in Germany
-
Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February
